Skip to main content
SpringerLink
Log in

The Impact of Pharmacogenomics in Personalized Medicine

  • Chapter
  • First Online:
Current Applications of Pharmaceutical Biotechnology

Part of the book series: Advances in Biochemical Engineering/Biotechnology ((ABE,volume 171))

Abstract

Recent advances in Pharmacogenomics have made it possible to understand the reasons behind the different response of a drug. Discovery of genetic variants and its association with the varying response of drug provide the basis for recommending a drug and its dose to an individual patient. Genetic makeup-based prescription, design, and implementation of therapy not only improve the outcome of treatments but also reduce the risk of toxicity and other adverse effects. A better understanding of individual variations and their effect on drug response, metabolism excretion, and toxicity will replace the trial-and-error approach of treatment. Evidence of the clinical utility of pharmacogenetics testing is only available for a few medications, and FDA labels only require pharmacogenetics testing for a small number of drugs. Although there is a great promise, there are not many examples where Pharmacogenomics impacts clinical utility. Some genetic variants related to different diseases have been reported, and many have not been studied yet. The information related to the outcome of treatment with a particular drug and a genetic variant can be used to release a warning/label for the use of that drug. There are many limitations in the way of implementing the goal of personalized medicine. Future advances in the field of genomics, diagnosis approaches, data analysis, clinical decision-making, and sustainable business model for personalization of therapy can speed up the individualization of therapy based on genetic makeup.

Graphical Abstract

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 299.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 379.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 379.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Hess GP, Fonseca E, Scott R, Fagerness J (2015) Pharmacogenomic and pharmacogenetic-guided therapy as a tool in precision medicine: current state and factors impacting acceptance by stakeholders. Genet Res (Camb) 97:e13. https://doi.org/10.1017/S0016672315000099

    Article  Google Scholar 

  2. NIH (2019) NIGMS: pharmacogenomics fact sheet. http://www.nigms.nih.gov/education/pages/factsheet-pharmacogenomics.aspx. Accessed 20 Apr 2019

  3. Kitzmiller JP, Groen DK, Phelps MA, Sadee W (2011) Pharmacogenomic testing: relevance in medical practice: why drugs work in some patients but not in others. Cleve Clin J Med 78:243–257

    Article  PubMed  PubMed Central  Google Scholar 

  4. Romualdi C, Balding D, Nasidze IS, Risch G, Robichaux M, Sherry ST, Stoneking M, Batzer MA, Barbujani G (2002) Patterns of human diversity, within and among continents, inferred from biallelic DNA polymorphisms. Genome Res 12:602–612

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Nadine C, Theresa F (2008) Challenges, opportunities, and evolving landscapes in pharmacogenomics and personalized medicine. In: Cohen N (ed) Pharmacogenomics and personalized medicine. Humana Press, Totowa, pp 1–26

    Google Scholar 

  6. Cho WC (2010) Recent progress in genetic variants associated with cancer and their implications in diagnostics development. Expert Rev Mol Diagn 10(6):699–703

    Article  CAS  PubMed  Google Scholar 

  7. Cirulli ET, Goldstein DB (2010) Uncovering the roles of rare variants in common disease through whole-genome sequencing. Nat Rev Genet 11(6):415–425

    Article  CAS  PubMed  Google Scholar 

  8. IGSR (2018) The International Genome Sample Resource. http://www.1000genomes.org/about. Accessed 02 Apr 2018

  9. International HapMap Consortium (2003) The international HapMap project. Nature 426:789–796

    Article  CAS  Google Scholar 

  10. Alomar MJ (2014) Factors affecting the development of adverse drug reactions (Review article). Saudi Pharm J 22:83–94

    Article  PubMed  Google Scholar 

  11. Soldin OP, Chung SH, Mattison DR (2011) Sex differences in drug disposition. J Biomed Biotechnol. https://doi.org/10.1155/2011/187103

  12. Ma Q, Lu AY (2011) Pharmacogenetics, pharmacogenomics, and individualized medicine. Pharmacol Rev 63:437–459

    Article  CAS  PubMed  Google Scholar 

  13. Hu Z, Yang X, Ho PC, Chan SY, Heng PW, Chan E, Duan W, Koh HL, Zhou S (2005) Herb-drug interactions: a literature review. Drugs 65:1239–1282

    Article  CAS  PubMed  Google Scholar 

  14. Zuo Z, Huang M, Kanfer I, Chow MS, Cho WC (2015) Herb-drug interactions: systematic review, mechanisms, and therapies. Evid Based Complement Alternat Med 2015:239150. https://doi.org/10.1155/2015/239150

    Article  PubMed  PubMed Central  Google Scholar 

  15. Singh DB (2017) Pharmacogenomics: clinical perspective, strategies, and challenges. In: Wei DQ, Ma Y, Cho W, Xu Q, Zhou F (eds) Translational bioinformatics and its application. Translational medicine research. Springer, Dordrecht, pp 299–333

    Chapter  Google Scholar 

  16. Martin MA, Kroetz DL (2013) Abacavir pharmacogenetics--from initial reports to standard of care. Pharmacotherapy 33:765–775

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Delaney C, Frank S, Huang RS (2015) Pharmacogenomics of EGFR-targeted therapies in non-small cell lung cancer: EGFR and beyond. Chin J Cancer 34:149–160

    Article  CAS  PubMed  Google Scholar 

  18. Dean L (2016) Aripiprazole therapy and CYP2D6 genotype. In: Pratt V, McLeod H, Rubinstein W, Dean L, Kattman B, Malheiro A (eds) Medical genetics summaries [Internet]. National Center for Biotechnology Information (US), Bethesda

    Google Scholar 

  19. Hashi S, Yano I, Shibata M, Masuda S, Kinoshita M, Matsumoto R, Ikeda A, Takahashi R, Matsubara K (2015) Effect of CYP2C19 polymorphisms on the clinical outcome of low-dose clobazam therapy in Japanese patients with epilepsy. Eur J Clin Pharmacol 71:51–58

    Article  CAS  PubMed  Google Scholar 

  20. Kim SH, Kim DH, Byeon JY, Kim YH, Kim DH, Lim HJ, Lee CM, Whang SS, Choi CI, Bae JW, Lee YJ, Jang CG, Lee SY (2017) Effects of CYP2C9 genetic polymorphisms on the pharmacokinetics of celecoxib and its carboxylic acid metabolite. Arch Pharm Res 40:382–390

    Article  CAS  PubMed  Google Scholar 

  21. Hagleitner MM, Coenen MJ, Patino-Garcia A, de Bont ES, Gonzalez-Neira A, Vos HI, van Leeuwen FN, Gelderblom H, Hoogerbrugge PM, Guchelaar HJ, Te Loo MW (2014) Influence of genetic variants in TPMT and COMT associated with cisplatin induced hearing loss in patients with cancer: two new cohorts and a meta-analysis reveal significant heterogeneity between cohorts. PLoS One 9:e115869

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  22. Lee SJ (2013) Clinical application of CYP2C19 pharmacogenetics toward more personalized medicine. Front Genet 3:318

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  23. Shirasaka Y, Sager JE, Lutz JD, Davis C, Isoherranen N (2013) Inhibition of CYP2C19 and CYP3A4 by omeprazole metabolites and their contribution to drug-drug interactions. Drug Metab Dispos 41:1414–1424

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. PharmGKB (2019) CPIC: Clinical Pharmacogenetics Implementation Consortium. https://www.pharmgkb.org/page/cpic. Accessed 03 Apr 2019

  25. CPIC (2019) Clinical Pharmacogenetics Implementation Consortium. https://cpicpgx.org. Accessed 03 Apr 2019

  26. PharmGKB (2019) DPWG: Dutch Pharmacogenetics Working Group. https://www.pharmgkb.org/page/dpwg. Accessed 03 Apr 2019

  27. Swen JJ, Nijenhuis M, de Boer A, Grandia L, Maitland-van der Zee AH, Mulder H, Rongen GA, van Schaik RH, Schalekamp T, Touw DJ, van der Weide J, Wilffert B, Deneer VH, Guchelaar HJ (2011) Pharmacogenetics: from bench to byte--an update of guidelines. Clin Pharmacol Ther 89:662–673

    Article  CAS  PubMed  Google Scholar 

  28. Ossorio P, Duster T (2005) Race and genetics: controversies in biomedical, behavioral, and forensic sciences. American Psychologist 60(1):115–128

    Article  PubMed  Google Scholar 

  29. Peterson-Iyer K (2008) Pharmacogenomics, ethics, and public policy. Kennedy Inst Ethics J 18(1):35–56

    Article  PubMed  Google Scholar 

  30. Redekop WK, Mladsi D (2013) The faces of personalized medicine: a framework for understanding its meaning and scope. Value Health 16(6 Suppl):S4–S9

    Article  PubMed  Google Scholar 

  31. Laing RE, Hess P, Shen Y, Wang J, Hu SX (2011) The role and impact of SNPs in pharmacogenomics and personalized medicine. Curr Drug Metab 12(5):460–486

    Article  CAS  PubMed  Google Scholar 

  32. Schwab M, Schaeffeler E (2012) Pharmacogenomics: a key component of personalized therapy. Genome Med 4(11):93

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Mousa AY, Broce M, Campbell J, Nanjundappa A, Stone PA, Abu-Halimah S, Srivastava M, Bates MC, Aburahma AF (2012) Clopidogrel use before renal artery angioplasty with/without stent placement resulted in tertiary procedure risk reduction. J Vasc Surg 56(2):416–423

    Article  PubMed  Google Scholar 

  34. Relling MV, Gardner EE, Sandborn WJ, Schmiegelow K, Pui CH, Yee SW, Stein CM, Carrillo M, Evans WE, Klein TE, Clinical Pharmacogenetics Implementation Consortium (2011) Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin Pharmacol Ther 89(3):387–391

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Renders L, Frisman M, Ufer M, Mosyagin I, Haenisch S, Ott U, Caliebe A, Dechant M, Braun F, Kunzendorf U, Cascorbi I (2007) CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant recipients. Clin Pharmacol Ther 81(2):228–234

    Article  CAS  PubMed  Google Scholar 

  36. Guinea J, Escribano P, Marcos-Zambrano LJ, Pela’ez T, Kestler M, Muñoz P, Vena A, López-Fabal F, Bouza E (2016) Therapeutic drug monitoring of voriconazole helps to decrease the percentage of patients with off-target trough serum levels. Med Mycol 54(4):353–360

    Article  CAS  PubMed  Google Scholar 

  37. Armitage J, Bowman L, Wallendszus K, Bulbulia R, Rahimi K, Haynes R, Parish S, Peto R, Collins R, Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group (2010) Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial. Lancet 376(9753):1658–1669

    Article  PubMed  CAS  Google Scholar 

  38. Druker BJ, Guilhot F, O’Brien SG et al (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355(23):2408–2417

    Article  CAS  PubMed  Google Scholar 

  39. Kwak EL, Bang YJ, Camidge DR et al (2010) Anaplastic lymphoma kinase inhibition in non–small-cell lung cancer. N Engl J Med 363(18):1693–1703

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Simon T, Verstuyft C, Mary-Krause M et al (2009) Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 360(4):363–375

    Article  CAS  PubMed  Google Scholar 

  41. Leypoldt F, Höftberger R, Titulaer MJ et al (2015) Investigations on CXCL13 in anti-N-methyl-D-aspartate receptor encephalitis: a potential biomarker of treatment response. JAMA Neurol 72(2):180–186

    Article  PubMed  PubMed Central  Google Scholar 

  42. Ramsey BW, Davies J, McElvaney NG et al (2011) A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 365:1663–1672

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Vandenbroucke JP, Koster T, Briët E, Reitsma PH, Bertina RM, Rosendaal FR (1994) Increased risk of venous thrombosis in oralcontraceptive users who are carriers of factor V Leiden mutation. Lancet 344(8935):1453–1457

    Article  CAS  PubMed  Google Scholar 

  44. O’Day E, Alsafar H (2018) Advanced diagnostics for personalized medicine. https://www.scientificamerican.com/article/advanced-diagnostics-for-personalized-medicine. Accessed 06 Apr 2019

  45. Dams SM, Crisamore KR, Empey PE (2018) Clinical pharmacogenomics: applications in nephrology. Clin J Am Soc Nephrol 13(10):1561–1571

    Article  Google Scholar 

  46. Jameson JL, Longo DL (2015) Precision medicine--personalized, problematic, and promising. N Engl J Med 372(23):2229–2234

    Article  CAS  PubMed  Google Scholar 

  47. Akinobu G (2014) Personalized medicine-based strategy for prostate cancer. Pers Med Univ 3:1–3

    Article  Google Scholar 

  48. Han MR, Zheng W, Cai Q, Gao YT, Zheng Y, Bolla MK, Michailidou K, Dennis J, Wang Q, Dunning AM, Brennan P, Chen ST, Choi JY, Hartman M, Ito H, Lophatananon A, Matsuo K, Miao H, Muir K, Sangrajrang S, Shen CY, Teo SH, Tseng CC, Wu AH, Yip CH, Kang D, Xiang YB, Easton DF, Shu XO, Long J (2017) Evaluating genetic variants associated with breast cancer risk in high and moderate-penetrance genes in Asians. Carcinogenesis 38(5):511–518

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Sultana N, Rahman M, Myti S, Islam J, Mustafa MG, Nag K (2019) A novel knowledge-derived data potentizing method revealed unique liver cancer-associated genetic variants. Hum Genomics 13(1)

    Google Scholar 

  50. Lilyquist J, Ruddy KJ, Vachon CM, Couch FJ (2018) Common genetic variation and breast cancer risk-past, present, and future. Cancer Epidemiol Biomarkers Prev 27:380–394

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Kar SP, Berchuck A, Gayther SA, Goode EL, Moysich KB, Pearce CL, Ramus SJ, Schildkraut JM, Sellers TA, Pharoah PDP (2018) Common genetic variation and susceptibility to ovarian cancer: current insights and future directions. Cancer Epidemiol Biomarkers Prev 27:395–404

    Article  CAS  PubMed  Google Scholar 

  52. Erdei E, Luo L, Sheng H, Maestas E, White KA, Mackey A, Dong Y, Berwick M, Morse DE (2013) Cytokines and tumor metastasis gene variants in oral cancer and precancer in Puerto Rico. PLoS One 8:e79187

    Article  PubMed  PubMed Central  Google Scholar 

  53. Engle JA, Kolesar JM (2014) Afatinib: a first-line treatment for selected patients with metastatic non-small-cell lung cancer. Am J Health Syst Pharm 71:1933–1938

    Article  CAS  PubMed  Google Scholar 

  54. Goss GD, Felip E, Cobo M, Lu S, Syrigos K, Lee KH, Göker E, Georgoulias V, Li W, Guclu S, Isla D, Min YJ, Morabito A, Ardizzoni A, Gadgeel SM, Fülöp A, Bühnemann C, Gibson N, Krämer N, Solca F, Cseh A, Ehrnrooth E, Soria JC (2018) Association of ERBB mutations with clinical outcomes of afatinib- or erlotinib-treated patients with lung squamous cell carcinoma: secondary analysis of the LUX-Lung 8 randomized clinical trial. JAMA Oncol 4:1189–1197

    Article  PubMed  PubMed Central  Google Scholar 

  55. Barratt DT, Somogyi AA (2017) Role of pharmacogenetics in personalised imatinib dosing. Transl Cancer Res 6:S1541–S1557

    Article  CAS  Google Scholar 

  56. Togneri FS, Ward DG, Foster JM, Devall AJ, Wojtowicz P, Alyas S, Vasques FR, Oumie A, James ND, Cheng KK, Zeegers MP, Deshmukh N, O’Sullivan B, Taniere P, Spink KG, McMullan DJ, Griffiths M, Bryan RT (2016) Genomic complexity of urothelial bladder cancer revealed in urinary cfDNA. Eur J Hum Genet 24(8):1167–1174

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Taly V, Pekin D, Benhaim L, Kotsopoulos SK, Le Corre D, Li X, Atochin I, Link DR, Griffiths AD, Pallier K, Blons H, Bouché O, Landi B, Hutchison JB, Laurent-Puig P (2013) Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients. Clin Chem 59(12):1722–1731

    Article  CAS  PubMed  Google Scholar 

  58. Nakamura Y (2015) Challenges and future directions of immunopharmacogenomics. In: Nakamura Y (ed) Immunopharmacogenomics. Springer, Tokyo, pp 159–162

    Chapter  Google Scholar 

  59. Deng X, Nakamura Y (2017) Cancer precision medicine: from cancer screening to drug selection and personalized immunotherapy. Trends Pharmacol Sci 38(1):15–24

    Article  CAS  PubMed  Google Scholar 

  60. Scheltens P, Blennow K, Breteler MM, de Strooper B, Frisoni GB, Salloway S, van der Flier WM (2016) Alzheimer’s disease. Lancet 388(10043):505–517

    Article  CAS  PubMed  Google Scholar 

  61. Lill CM (2016) Genetics of Parkinson’s disease. Mol Cell Probes 30:386–396

    Article  CAS  PubMed  Google Scholar 

  62. Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, Hsu PD, Wu X, Jiang W, Marraffini LA, Zhang F (2013) Multiplex genome engineering using CRISPR/Cas systems. Science 339(6121):819–823

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Raffel J, Wakerley B, Nicholas R (2016) Multiple sclerosis. Medicine 44(9):537–541

    Article  Google Scholar 

  64. Chatawa J (2017) Treating clinically isolated syndrome: the long game. J Neurol Neurosurg Psychiatry 88(4):284

    Article  Google Scholar 

  65. Stilund M, Reuschlein AK, Christensen T, Møller HJ, Rasmussen PV, Petersen T (2014) Soluble CD163 as a marker of macrophage activity in newly diagnosed patients with multiple sclerosis. PLoS One 9(6):e98588

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  66. Nagalla S, Bray PF (2016) Personalized medicine in thrombosis: back to the future. Blood 127(22):2665–2671

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Johnson JA (2012) Warfarin pharmacogenetics: a rising tide for its clinical value. Circulation 125(16):1964–1966

    Article  PubMed  PubMed Central  Google Scholar 

  68. Mega JL, Walker JR, Ruff CT et al (2015) Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet 385(9984):2280–2287

    Article  CAS  PubMed  Google Scholar 

  69. Leonard D, Svenungsson E, Dahlqvist J, Alexsson A, Ärlestig L, Taylor KE, Sandling JK, Bengtsson C, Frodlund M, Jönsen A, Eketjäll S, Jensen-Urstad K, Gunnarsson I, Sjöwall C, Bengtsson AA, Eloranta ML, Syvänen AC, Rantapää-Dahlqvist S, Criswell LA, Rönnblom L (2018) Novel gene variants associated with cardiovascular disease in systemic lupus erythematosus and rheumatoid arthritis. Ann Rheum Dis. 77(7):1063–1069

    Article  CAS  PubMed  Google Scholar 

  70. Christiansen MK, Larsen SB, Nyegaard M, Neergaard-Petersen S, Ajjan R, Würtz M, Kristensen SD (2017) Coronary artery disease-associated genetic variants and biomarkers of inflammation. PloS one 12(7):e0180365

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  71. LeBlanc M, Zuber V, Andreassen BK, Witoelar A, Zeng L, Bettella F, Wang Y, McEvoy LK, Thompson WK, Schork AJ, Reppe S, Barrett-Connor E, Ligthart S, Dehghan A, Gautvik KM, Nelson CP, Schunkert H, Samani NJ, CARDIoGRAM Consortium, Ridker PM, Chasman DI, Aukrust P, Djurovic S, Frigessi A, Desikan RS, Dale AM, Andreassen OA (2016) Identifying novel gene variants in coronary artery disease and shared genes with several cardiovascular risk factors. Circ Res 118(1):83–94

    Article  CAS  PubMed  Google Scholar 

  72. Soliday FK, Conley YP, Henker R (2010) Pseudocholinesterase deficiency: a comprehensive review of genetic, acquired, and drug influences. AANA J 78(4):313–320

    PubMed  Google Scholar 

  73. Kaye AD, Mahakian T, Kaye AJ, Pham AA, Hart BM, Gennuso S, Cornett EM, Gabriel R, Urman RD (2018) Pharmacogenomics, precision medicine, and implications on anesthesia care. Best Pract Res Clin Anaesthesiol 32:61–81. https://doi.org/10.1016/j.bpa.2018.07.001

    Article  PubMed  Google Scholar 

  74. Palmer SN, Giesecke NM, Body SC, Shernan SK, Fox AA, Collard CD (2005) Pharmacogenetics of anesthetic and analgesic agents. Anesthesiology 102(3):663–671

    Article  CAS  PubMed  Google Scholar 

  75. Fitipaldi H, McCarthy MI, Florez JC, Franks PW (2018) A global overview of precision medicine in type 2 diabetes. Diabetes 67(10):1911–1922

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  76. Moltke I, Grarup N, Jørgensen ME et al (2014) A common Greenlandic TBC1D4 variant confers muscle insulin resistance and type 2 diabetes. Nature 512(7513):190–193

    Article  CAS  PubMed  Google Scholar 

  77. Estrada K, Aukrust I, Bjørkhaug L, SIGMA Type 2 Diabetes Consortium et al (2014) Association of a low-frequency variant in HNF1A with type 2 diabetes in a Latino population. JAMA 311:2305–2314

    Article  PubMed  CAS  Google Scholar 

  78. Zhou K, Yee SW, Seiser EL, MetGen Investigators; DPP Investigators; ACCORD Investigators et al (2016) Variation in the glucose transporter gene SLC2A2 is associated with glycemic response to metformin. Nat Genet 48(9):1055–1059

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  79. Perlis RH (2014) Pharmacogenomic testing and personalized treatment of depression. Clin Chem. 60(1):53–59. https://doi.org/10.1373/clinchem.2013.204446

    Article  CAS  PubMed  Google Scholar 

  80. Samer CF, Lorenzini KI, Rollason V, Daali Y, Desmeules JA (2013) Applications of CYP450 testing in the clinical setting. Mol Diagn Ther 17(3):165–184

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  81. Lobello KW, Preskorn SH, Guico-Pabia CJ, Jiang Q, Paul J, Nichols AI, Patroneva A, Ninan PT (2010) Cytochrome P450 2D6 phenotype predicts antidepressant efficacy of venlafaxine: a secondary analysis of 4 studies in major depressive disorder. J Clin Psychiatry 71(11):1482–1487

    Article  CAS  PubMed  Google Scholar 

  82. Finch RA, Sartorelli AC, Piwnica-Worms D (1999) Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal fluid drug-permeability barrier. Proc Natl Acad Sci U S A 96(7):3900–3905

    Article  PubMed  PubMed Central  Google Scholar 

  83. de Leon J (2009) The future (or lack of future) of personalized prescription in psychiatry. Pharmacol Res 59(2):81–89

    Article  PubMed  Google Scholar 

  84. de Leon J (2006) The AmpliChip CYP450 test: personalized medicine has arrived in psychiatry. Expert Rev Mol Diagn 6(3):277–286

    Article  PubMed  Google Scholar 

  85. Filaković P, Petek A (2009) Personalized pharmacotherapy in psychiatry. Psychiatr Danub 21(3):341–346

    PubMed  Google Scholar 

  86. Skrętkowicz J, Barańska M, Rychlik-Sych M (2013) Clinical significance of pharmacogenetics in psychiatry. Wiad Lek 66(2 Pt 2):185–191

    PubMed  Google Scholar 

  87. Spina E, de Leon J (2015) Clinical applications of CYP genotyping in psychiatry. J Neural Transm (Vienna) 122(1):5–28

    Article  CAS  Google Scholar 

  88. Arneet DK, Class SA, Glasser SP (2006) Pharmacogenetics of antihypertensive treatment. Vasc Pharmacol 44(2):107–118

    Article  CAS  Google Scholar 

  89. Johnson JA, Zineh I, Puckett BJ, McGorray SP, Yarandi HN, Pauly DF (2003) Beta 1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol. Clin Pharmacol Ther 74(1):44–52

    Article  CAS  PubMed  Google Scholar 

  90. Bengtsson K, Melander O, Orho-Melander M (2001) Polymorphism in the beta(1)-adrenergic receptor gene and hypertension. Circulation 104(2):187–190

    Article  CAS  PubMed  Google Scholar 

  91. Shin J, Lobmeyer MT, Gong Y (2007) Relation of beta(2)-adrenoceptor haplotype to risk of death and heart transplantation in patients with heart failure. Am J Cardiol 99(2):250–255

    Article  CAS  PubMed  Google Scholar 

  92. Cooper-DeHoff RM, Johnson JA (2016) Hypertension pharmacogenomics: in search of personalized treatment approaches. Nat Rev Nephrol 12(2):110–122

    Article  CAS  PubMed  Google Scholar 

  93. Byrd JB (2016) Personalized medicine and treatment approaches in hypertension: current perspectives. Integr Blood Pressure Control 9:59–67

    Article  CAS  Google Scholar 

  94. Kushner J (2014) The ethics of personalized medicine. Pers Med Univ 3:42–45

    Article  Google Scholar 

  95. Relling M (2015) Clinical implementation of pharmacogenetics: CPIC guidelines. Clin Chem Lab Med 53:S75

    Google Scholar 

  96. Jansen ME, Rigter T, Rodenburg W, Fleur TMC, Houwink EJF, Weda M, Cornel MC (2017) Review of the reported measures of clinical validity and clinical utility as arguments for the implementation of pharmacogenetic testing: a case study of statin-induced muscle toxicity. Front Pharmacol 8:555

    Article  PubMed  PubMed Central  Google Scholar 

  97. Tonk EC, Gurwitz D, Maitland-van der Zee AH, Janssens AC (2016) Assessment of pharmacogenetic tests: presenting measures of clinical validity and potential population impact in association studies. Pharmacogenomics J 17:386–392

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  98. Vogenberg FR, Isaacson Barash C, Pursel M (2010) Personalized medicine: part 1: evolution and development into theranostics. P T 35(10):560–576

    PubMed  PubMed Central  Google Scholar 

  99. Atutornu J, Hayre CM (2018) Personalized medicine and medical imaging: opportunities and challenges for contemporary health care. J Med Imaging Radiat Sci 49(4):352–359

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Biotechnology, Institute of Biosciences and Biotechnology, Chhatrapati Shahu Ji Maharaj University, Kanpur, Uttar Pradesh, India

    Dev Bukhsh Singh

Authors
  1. Dev Bukhsh Singh
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. UCIBIO, REQUIMTE, MEDTECH, Laboratory of Pharmaceutical Technology, Department of Drug Sciences, Faculty of Pharmacy, University of Porto, Porto, Portugal

    Ana Catarina Silva

  2. FP-ENAS (UFP Energy, Environment and Health Research Unit), CEBIMED (Biomedical Research Centre), Faculty of Health Sciences, Fernando Pessoa University, Porto, Portugal

    Ana Catarina Silva

  3. Center for Neurosciences and Cell Biology (CNC) and Faculty of Pharmacy (FFUC), University of Coimbra, Coimbra, Portugal

    João Nuno Moreira

  4. UCIBIO, REQUIMTE, MEDTECH, Laboratory of Pharmaceutical Technology, Department of Drug Sciences, Faculty of Pharmacy, University of Porto, Porto, Portugal

    José Manuel Sousa Lobo

  5. UCIBIO, REQUIMTE, MEDTECH, Laboratory of Pharmaceutical Technology, Department of Drug Sciences, Faculty of Pharmacy, University of Porto, Porto, Portugal

    Hugo Almeida

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Singh, D.B. (2019). The Impact of Pharmacogenomics in Personalized Medicine. In: Silva, A.C., Moreira, J.N., Lobo, J.M.S., Almeida, H. (eds) Current Applications of Pharmaceutical Biotechnology. Advances in Biochemical Engineering/Biotechnology, vol 171. Springer, Cham. https://doi.org/10.1007/10_2019_110

Download citation

Publish with us

Policies and ethics

Search

Navigation